Recent developments of interest in cardiovascular medicine ...

Discover the impact of digital pathology on drug discovery and biomarker research this International Women’s Day with Dr ...

Dyne has aligned with the U.S. Food and Drug Administration (FDA) on the HARMONIA Phase 3 trial design and protocol. HARMONIA is intended to serve as a confirmatory trial to support conversion of ...

CI&T Inc (CINT) reports a robust 19.3% organic revenue growth in Q4 2025, fueled by AI integration and strong client engagement, despite facing foreign exchange challenges.

Although they lack a single shared definition of wisdom, many are optimistic that the capacity can be cultivated. “Not everyone will become a super wisdom guru,” says Judith Glück, a developmental ...

Dyne Therapeutics has initiated the Phase III HARMONIA trial to evaluate the efficacy, safety, and tolerability of zeleciment basivarsen (z-basivarsen, also called DYNE-101) in individuals diagnosed ...

NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravisAarhus, ...

The MarketWatch News Department was not involved in the creation of this content. -- NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in ...

Lithium-a decades-old treatment for bipolar disorder-may hold potential neuroprotective benefits beyond mood stabilization.An ...

这项试验有两个主要目标：第一，评估在无先兆偏头痛患者中，真针灸是否比假针灸更有效。第二，通过基于机器学习的脑连接组模型，确定基线静息态功能连接性能否预测针灸后的临床改善。

Therapies backed only by lower-tier evidence no better than unmatched treatment ...